Cancer immunotherapy is considered to be one of the alternatives to traditional chemotherapy. It's known that foreign antigen, such as ovalbumin (OVA), can label tumor cells, leading to neoantigen recognition by cytotoxic T lymphocytes. Herein, a novel multifunctional micelle coated with PEGylated hyaluronic acid (HA) was prepared through self-assembly and electrostatic interaction. The OVA-loaded micelle with uniform size (132.1 ± 0.2 nm in diameter) exhibited favorable stability and sustained release profiles. The HA-coated micelle could target CD44-overexpressed cells and enhance the cellular uptake of OVA by 11.9 fold compared to free OVA. In vitro studies revealed that the cationic polymer, polyethyleneimine, could facilitate endosomal escape of OVA to label a tumor cell. After treatment with the OVA-loaded micelle, tumor growth in mice was significantly inhibited by 70% compared to the group treated with free OVA. All these results suggest the potential application of the immunotherapeutic micellar platform for melanoma treatment.
Introduction
Traditional cancer therapy has to commonly rely on chemotherapy, which is however unfortunately limited due to adverse side effects, drug resistance and unsatisfactory therapeutic efficacy (Vanneman and Dranoff, 2012; Savla et al., 2014) . In the last two decades, cancer immunotherapy has become one of the most promising treatment strategies for various types of tumors, such as melanoma (Vasievich et al., 2012; Rosalia et al., 2015) and ovarian cancer (Cubillosruiz et al., 2009; Teo et al., 2015) , achieving the enhanced tumor inhibition efficacy without damaging normal cells through modulation of specific tumor immune response (Blattman and Greenberg, 2004) . Cytotoxic T lymphocytes (CTLs), including CD8 + cytotoxic lymphocytes, can selectively and effectively kill tumor cells due to their ability to recognize a specific antigen, as a result of the presence of the antigen on the surface of dendritic cells (DCs) following its binding to major histocompatibility complex (MHC) class I molecules (Sotomayor et al., 2001; Guermonprez et al., 2002; Russell and Ley, 2002; Friedl et al., 2005) . Therefore, increasing interest has been paid to the use of protein antigens for cancer immunotherapy (Bachelder et al., 2010) . The K brestricted ovalbumin (OVA)-derived epitope, SIINFEKL, has been reported to facilitate efficient MHC I presentation and generate OVAspecific CD8 + CTLs in vivo in DCs (Higgins et al., 1999; Radford et al., T to antigen presenting cells (APCs) (Sahdev et al., 2014; Fan et al., 2015) . Nanoparticles have been demonstrated to show long circulation time in blood and reduce clearance by the mononuclear phagocyte system (MPS) (Van, 1982; Gref et al., 1994; Howard et al., 2008; Alexis et al., 2008; Nel et al., 2009) . Their surface charge and size (should be smaller than 200 nm) are required to be manipulated to facilitate escape from phagocytosis of liver cells (Alexis et al., 2008) . Surface modification of nanoparticles with stealth molecules such as polyethylene glycol (PEG) has been widely applied to increase circulation time (Ye et al., 2013; Yu and Jee, 2016; Yan et al., 2016) . In this paper, we report a novel multifunctional micelle, which is prepared through self-assembly of the PEI grafted with vitamin E succinate (VES), VES-g-PEI, followed by OVA loading and surface coating with the mixture of hyaluronic acid (HA) and PEGylated HA (mPEG-g-HA), through electrostatic interaction (Fig. 1) . The self-assembled micelle has stable structure and can reach tumors through the enhanced permeability and retention (EPR) effect. PEI, as an immunologic adjuvant, can cause immunological activity mediated by Toll-like receptors (TLRs) , is also used in cancer immunotherapy (Hanmei et al., 2017; Mahboubeh et al., 2017) . However, PEI, especially the high-molecular-weight one, is limited for its high cytotoxicity (Yim et al., 2013; Hu et al., 2013) . Herein, the targeting ligand HA with abundant negative charge is employed to not only neutralize positive charge of PEI chains thus decreasing cytotoxicity, but also effectively improve cellular uptake of the micelle in the melanoma cell overexpressed with HA receptors, CD44. After HA receptormediated endocytosis (Lee et al., 2015) , the outer layer of the micelle can be degraded by hyaluronidases , and as a result, PEI can assist OVA escaping from endosomes into the cytoplasm. This leads to formation of MHC class I epitope OVA 257-264 on the tumor cell surface and its consequent recognition by DCs and recruitment of antigen-specific CD8 + T cells to kill cancer cells (Fig. 1 ).
Materials and methods

Materials
Polyethyleneimine (PEI, M W = 25 kDa), hyaluronic acid (HA, M W = 180 kDa), methoxy polyethylene glycol-amine (mPEG-NH 2 , M W = 2 kDa), ovalbumin (OVA), IR-775 chloride, pentobarbital sodium and methyl thiazolyl tetrazolium (MTT) were purchased from Sigma (St. Louis, USA). 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC·HCl) and N-hydroxysuccinimide (NHS) were purchased from Damas (Shanghai, China). Vitamin E Succinate (VES) was purchased from TCI Co. Ltd (Shanghai, China). FITC was purchased from Santa Cruz (California, USA). Hochest33258 and bicinchoninic acid (BCA) protein assay kit were purchased from Beyotime Institute of Biotechnology Co. Ltd (Shanghai, China). All reagents used in this study were analytically pure grade unless otherwise stated.
Phosphate buffered saline (PBS), Dulbecco's Modified Eagle's Medium (DMEM) and penicillin-streptomycin were purchased from Hyclone Company (Logan, Utah, USA). Pancreatin and fetal bovine serum (FBS) were purchased from Zhejiang Tianhang Biological Science Co. Ltd (Zhejiang, China). Lysotracker Red was purchased from Life Tech (Delhi, India).
Mouse melanoma cell line B16-F10 was obtained from Chinese Academy of Sciences Cell Literary (Shanghai, China). C57BL/6 mice (female, 6-8 weeks, 20 ± 5 g) were purchased from Slaccas Experimental Animal Co. Ltd (Shanghai, China). The animal experiments were carried out in accordance with the guidelines evaluated and 
Synthesis of VES-g-PEI
The synthetic route of VES-g-PEI is shown in Fig. 2A . Briefly, 50 mg PEI was dissolved in dimethyl sulfoxide (DMSO) to obtain 25 mg ml −1 PEI solution. 31.8 mg VES was dissolved in DMSO, to which NHS and EDC·HCl was added. After magnetic stirring at 25°C for 30 min, PEI solution was added dropwise into VES solution under magnetic stirring for 24 h at 25°C with protection from light. The reaction solution was purified by dialysis (molecular weight cut off 8-12 kDa) against DMSO for 1 day, followed by dialysis against deionized water for 3 days. VESg-PEI was then obtained through freeze-drying of the dialysate. The structure of VES-g-PEI was confirmed with 1 H NMR on a Bruker AVANCE 400 spectrometer at 400 MHz and FT-IR on a Nicolet 6700 spectrometer. The degree of substitution of the amino groups of PEI with VES was calculated by elemental analysis. Critical micelle concentration (CMC) of VES-g-PEI was determined using pyrene as a fluorescent probe (Duan et al., 2016) . The proton buffering capability of VES-g-PEI was measured through acid-base titration (Hu et al., 2013) .
Synthesis of mPEG-g-HA
The synthetic route of mPEG-g-HA is shown in Fig. 2B . Briefly, 100 mg HA was dissolved overnight in 10 mL deionized water. NHS and EDC·HCl were added into the HA solution under magnetic stirring for 2 h at 25°C. 49.6 mg mPEG-NH 2 was dissolved in 10 mL deionized water, to which the HA mixture was added under continually stirring. The reaction stood for 24 h with nitrogen protection at 25°C. The reaction solution was purified by dialysis (molecular weight cut off 8-12 kDa) against deionized water for 3 days. mPEG-g-HA was then obtained through freeze-drying of the dialysate. The structure of mPEGg-HA was confirmed with 1 H NMR on a Bruker AVANCE 400 spectrometer at 400 MHz and FTIR on a Nicolet 6700 spectrometer.
Preparation and characterization of the OVA@mPEG-g-HA/VES-g-PEI micelle
The pH of the 1.0 mg mL −1 VES-g-PEI aqueous solution was adjusted to 7.4, and then sonicated (100 w, 1 s pulse/1 s pause) using a BILON92 sonicator for 5 min to obtain the self-assembled VES-g-PEI micelle. OVA aqueous solution (1.0 mg mL −1
) was added dropwise into the VES-g-PEI micelle solution, to which mPEG-g-HA was then added dropwise to obtain the OVA@mPEG-g-HA/VES-g-PEI micelle.
Micelle size, polydispersity index (PI), and surface charge were measured by dynamic light scattering (DLS) using a Nano-ZS90 Zetasizer (Malvern, UK).
The morphology of the micelle was observed by transmission electron microscopy (TEM). Briefly, the OVA@mPEG-g-HA/VES-g-PEI micelle solution was dropped onto EM grids, after drying for 30 min, the samples were stained with 1% phosphotungstic acid. The dried grids were examined using a JEM-1400 transmission electron microscope (Tokyo, Japan) at 120 kV.
Proton buffering capabilities
Buffering capacity was determined by acid-base titration. Briefly, 10 mg of PEI and VES-g-PEI was dissolved in 10 mL of 150 mM NaCl solution, and the pH was set to 10.0 using 0.1 M NaOH. The pH change was recorded with the increasing volume of HCl titrant (0.1 M). The consumed volume of HCl in the pH interval from 10.0 to 3.0 can be used to evaluate the proton buffering capability of the polymer.
OVA entrapment efficiency (EE) and loading efficiency (LE)
Entrapment efficiency and loading efficiency were determined by BCA assay. Briefly, OVA@mPEG-g-HA/VES-g-PEI micelle solution was centrifuged at 12,000 rpm for 30 min at 4°C, and then the supernatant was collected to test the amount of OVA using the BCA kit according to supplier's instructions. The precipitate was resuspended using deionized water, and then freeze-dried to obtain the OVA@mPEG-g-HA/ VES-g-PEI powder. Entrapment efficiency and loading efficiency were calculated as below respectively.
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Stability of the OVA@mPEG-g-HA/VES-g-PEI micelle
The OVA@mPEG-g-HA/VES-g-PEI micelle solution was stored at 4°C for 14 days. The micelle size was measured every two days by DLS using a Nano-ZS90 Zetasizer.
In vitro release of OVA
The OVA@mPEG-g-HA/VES-g-PEI micelle solution was resuspended in phosphate buffer solution (PBS, pH 7.4) at a final concentration of 0.1% (w/v), and then was vibrated slowly in 37°C water bath at 100 rpm. At a specific time internal (1, 2, 4, 12, 24, 36, 48, 60, 72 h) , 200 μL aliquots were collected and replaced with an equal volume of fresh medium. Each aliquot was centrifuged at 10,000 rpm for 0.5 h to separate the supernatant for determination of the amount of released OVA by BCA assay. 
In vitro cytotoxicity
B16-F10 cells were seeded in 96-well plates at the density of 10 4 cells per well. After 24-hour incubation, the micelle solution at a specific concentration ranging from 1 to 120 µg mL −1 was added. After incubation for 48 h, 20 µL MTT solution (5 mg mL −1 ) was added to each well followed by incubation for 4 h, and then 200 µL DMSO was added to dissolve resulting formazan crystals. The absorbance at 570 nm of each well was measured using a Tecan Safire 2 microplate reader (Männedorf, Switzerland).
Fluorescence microscopy
B16-F10 cells were seeded into 18-mm glass-bottom dishes at 2 × 10 5 cells per well overnight. The cells were washed twice with PBS and then treated with the FITC-OVA (10 μg mL −1 ) loaded micelles in DMEM for 2 h. The cell nuclei were stained with 2 μL Hoechst 33,258 at 37°C for 20 min and then washed twice with cold PBS before fluorescent microscopy using a Nikon Ti-S inverted microscope (Tokyo, Japan).
Confocal microscopy
B16-F10 cells were seeded into 96-well plates at the density of 10 5 cells per well overnight . The cells were washed twice with PBS, treated with the FITC-OVA (10 μg mL −1 ) loaded micelles in DMEM for 2 h, and then washed three times using cold PBS. The lysosome was stained with Lysotracker Red (1 μL) at 37°C for 1 h. The cells were fixed with 4% paraformaldehyde for 20 min and then washed three times using cold PBS. The nucleus was stained by Hochest 33,258 before measurement using a Nikon A1R confocal microscope (Tokyo, Japan).
Generation and stimulation of dendritic cells
Bone marrow-derived dendritic cells (BMDC) were harvested from male 8-week-old C57BL/6 mice and cultivated for 8 days as previous reported (Hirosue et al., 2010) . Briefly, bone marrow cells were flushed out with RPMI 1640 from femurs and tibiae and passed through a 70 μm nylon cell strainer to remove debris. The red blood cells were lysed and the remaining cell suspensions were centrifuged and resuspended in fresh RPMI 1640 medium supplemented with 10% FBS, 100 U mL −1 penicillin and 100 μg mL −1 streptomycin, 0.2 mM L-glutamine, at the presence of 20 ng mL −1 recombinant murine GM-CSF (PeproTech, NJ, USA). Cells were cultured in six-well plates at 37 ℃ for 7 days. On day 8 of culturing, 10 μg mL −1 LPS, OVA or OVA@mPEG-g-HA/VES-g-PEI micelle were added to make the concentration of OVA was 50 μg mL −1
, the cells were continued culturing for 2 days, the cells were collected to detect the maturity. Briefly, cells were washed with PBS and to form a single cell suspension, Fluorochrome-labeled antimouse monoclonal antibodies CD40 and CD80 (Biolegend, CA, USA) was used to stain cells on ice for 30 min. Cells were washed with cold PBS and immediately analyzed on flow cytometry (FACSJazz, BD Biosciences, San Jose, CA, USA).
Antigen presentation assay
B16-F10 cells at logarithmic phase were seeded into 6-well plates at the density of 2 × 10 5 cells per well overnight . The cell was treated with the solution of the OVA (10 μg mL −1
) loaded micelle for 12 h. The cells were then treated with the anti-mouse OVA 257-264 peptide bound to phycoerythrin (PE) (1 μg) for 30 min at 4°C, and the OVA presentation was quantified by flow cytometry using a BD Biosciences FACS Jazz cell sorter (San Jose, USA).
Tumor-bearing mouse model
All animal experiments were carried out in accordance with guidelines evaluated and approved by the ethics committee of the East China University of Science and Technology.
To measure the in vivo anti-tumor efficacy of the OVA@mPEG-g-HA/VES-g-PEI micelle, the C57BL/6 female mouse model bearing melanoma was established by subcutaneously inoculating mice with B16-F10 cells (0.1 mL, 1.0 × 10 7 cells mL −1
), and was then randomly divided into different experimental groups.
In vivo biodistribution of the OVA@mPEG-g-HA/VES-g-PEI micelle
IR-775 chloride, a near-infrared fluorescent dye with an excitation wavelength of 774 nm and an emission wavelength of 792 nm, was used to reveal in vivo distribution of the OVA@mPEG-g-HA/VES-g-PEI micelle. Briefly, mice randomly divided into two groups were individually injected via tail vein with 0.1 mL IR-775 loaded VES-g-PEI micelle and IR-775 loaded mPEG-g-HA/VES-g-PEI micelle respectively. Six hours later, the mice were sacrificed and major organs (heart, liver, spleen, lung, kidney and tumor) were excised and rinsed with saline. Images were obtained using a Carestream In-vivo Imaging FX System (excitation wavelength of 770 nm, emission wavelength of 810 nm).
In vivo anti-tumor efficacy
In order to generate OVA immune responses, each mouse was immunized with OVA@mPEG-g-HA/VES-g-PEI micelle at a dose of 1 mg OVA/kg subcutaneously every day for one week until they bore tumors. Seven days after the tumor-bearing mouse model was established, those mice were intravenously injected via tail vein with 0.1 mL OVA, the OVA@VES-g-PEI micelle and the OVA@mPEG-g-HA/VES-g-PEI micelle at the dose of 1 mg OVA/kg once every two days for six times. The mice were treated with saline of the same volume as control. Tumor size was measured every three days using a slide caliper and the tumor volume (volume = length × width 2 /2, mm 3 ) and mouse weight were then recorded.
Statistical analysis
Multiple group comparisons were conducted using one-way analysis of variance (ANOVA). All data analysis was carried out using the IBM SPSS Statistics 17.0. All data were presented as a mean value with its standard deviation indicated (mean ± SD). P-values < 0.05 were considered to be statistically significant.
Results and discussion
Characterization of VES-g-PEI and mPEG-g-HA
In the 1 H NMR spectrum of VES-g-PEI (Fig. S1A) , there were characteristic absorption peaks corresponding to VES methyl, methylene and methine at around 1.0-1.25 ppm. In addition, the peaks corresponding to N-H (3440 cm and C-H (2927 cm −1 ) in VES-g-PEI were observed in its FTIR spectrum (Fig. S1B) . The evident peaks of amide bonds, which are not present in the FTIR spectra of PEI or VES, suggest successful synthesis of VES-g-PEI. The degree of substitution (DS) of the amine groups of PEI with VES was determined to be 5.8% by elemental analysis. The 1 H NMR spectrum of mPEG-g-HA (Fig. S1C) shows the characteristic absorption peaks corresponding to the methine (δ = 3.2-3.7 ppm) and acetyl protons (δ = 1.9 ppm) of HA, as well as the methylene (δ = 3.5-3.7 ppm) and methoxy protons (δ = 3.25 ppm) of mPEG were observed. The DS of mPEG in mPEG-g-HA was determined to be 11.7%. In addition, enhanced stretching vibration of amide bonds (1660 cm −1
) was observed in FTIR spectrum of mPEG-g-HA as compared to HA, suggesting the successful synthesis of mPEG-g-HA. (Fig. S1D) 
Proton buffering capability and CMC of VES-g-PEI
PEI has been reported to facilitate endosomal escape of antigen from the endosome into the cytoplasm via the 'proton sponge' effect . Herein, the acid-base titration measurement was carried out to evaluate the proton buffering capacity of VES-g-PEI at pH typical of endosomes. (Fig. S2A) The volume of 0.1 M HCl required to titrate toward the specific pH range showed that VES-g-PEI possessed significant proton buffering capability compared to NaCl solution. VES-g-PEI exhibited reduced proton buffering capacity than PEI alone, which was attributed to substitution of the primary amine groups of PEI with VES. The relatively low CMC of VES-g-PEI at 20.7 μg mL −1 (Fig. S2B) suggests that it could form stable hydrophobic micelle in aqueous solution (Mekhail et al., 2012) .
Characterization of the OVA@mPEG-g-HA/VES-g-PEI micelle
As shown in Fig. 3 , the OVA@mPEG-g-HA/VES-g-PEI micelle displayed spherical morphology and smooth surface. The hydrodynamic size of the micelle measured by DLS was 132.1 ± 0.2 nm in diameter and the size measured by TEM was around 80 nm (Fig. 3D) . Table 1 summarizes the effect of feeding weight ratio of OVA relative to VES-g-PEI on physicochemical properties of the OVA@VES-g-PEI micelle. With increasing the weight ratio of OVA/VES-g-PEI from 0/ 1 to 0.5/1, the hydrodynamic diameter of the micelle showed a negligible change within the range of 84.4-88.5 nm. However, with further increasing the weight ratio of OVA/VES-g-PEI from 1/1 to 4/1, the micelle size was increased considerably from 96.7 ± 1.3 nm to 212.8 ± 5.7 nm respectively. At physiological pH, PEI is positively charged and OVA negatively charged, thus enabling OVA loading through electrostatic interaction. Increasing the amount of OVA to a sufficiently high level could cause a remarkable increase in the micelle size and polydispersity (PI) probably due to the enhanced aggregation resulting from the decrease in net surface charge. This is evidence by the gradual decrease in zeta potential of the micelle from 62.2 ± 3.4 mV to −1.2 ± 1.2 mV upon increasing the weight ratio of OVA/VES-g-PEI from 0/1 to 4/1. It is also worth pointing out that with increasing the weight ratio of OVA/VES-g-PEI up to 0.5/1, the loading efficiency was significantly enhanced to 28.8 ± 2.6% whilst retaining the high encapsulation efficiency of 90.6 ± 1.8%. However, a further increase in the weight ratio of OVA/VES-g-PEI from 1/1 to 4/1 led to a small increase in LE from 37.9 ± 3.8% to 42.2 ± 6.6% but a considerable decease in EE from 80.4 ± 3.4% to 24.7 ± 7.6%.
PEI has been reported to demonstrate rapid clearance by mononuclear phagocyte system (MPS), unfavorable biodistribution and nonspecific high cytotoxicity due to its high positive charge density (Yim et al., 2013) . To address those issues, herein, surface coating of the OVA@VES-g-PEI micelle with HA with abundant negative charge was carried out to further manipulate the net surface charge and the introduction of mPEG-g-HA would provide the extra shielding effect. The 
Table 1
Physicochemical properties of the OVA@VES-g-PEI micelle prepared at different feeding weight ratios of OVA relative to VES-g-PEI. (Mean ± SD, n = 5). 88.5 ± 0.2 31.8 ± 0.2 90.6 ± 1.8 28.8 ± 2.6 0.11 1/1 96.7 ± 1.3 16.7 ± 1.0 80.4 ± 3.4 37.9 ± 3.8 0.13 2/1 129.9 ± 3.4 4.6 ± 0.3 43.9 ± 5.3 40.8 ± 5.3 0.14 4/1 212.8 ± 5.7 −1.2 ± 1.2 24.7 ± 7.6 42.2 ± 6.6 0.35 Note: EE: entrapment efficiency. LE: loading efficiency. PI: polydispersity index.
net surface charge of the micellar structure could be manipulated to significantly decrease its cytotoxicity (Fig. 3C ) whilst well retain its stability (Fig. 3A) . Furthermore, HA can selectively target the CD44 receptor overexpressed on the surface of tumor cells. Table 2 summarizes the effect of feeding weight ratios of mPEG-g-HA relative to VES-g-PEI on physicochemical properties of the OVA@mPEG-g-HA/ VES-g-PEI micelle when the feeding weight ratio of OVA/VES-g-PEI was fixed at 0.5/1. Amine groups of PEI were associated with the carboxyl groups of HA through electrostatic interaction. This leads to a gradual increase in the hydrodynamic micelle diameter from 84.4 ± 6.5 nm to 132.1 ± 1.3 nm and a concurrent decrease in the net surface charge from 33.4 ± 0.9 mV to −42.0 ± 1.2 mV when the weight ratio of mPEG-g-HA/VES-g-PEI was increased from 0/1 to 3/1. The feeding weight ratios of OVA/VES-g-PEI and mPEG-g-HA/VES-g-PEI were optimized to be 0.5/1 and 2/1 respectively for the following study. The resulting OVA@mPEG-g-HA/VES-g-PEI micelle had the hydrodynamic diameter at 132.1 ± 0.2 nm, zeta potential at −35.1 ± 1.5 mV, EE at 90.6 ± 1.8%, and LE at 13.6 ± 3.0%, respectively. Fig. 3A shows that the hydrodynamic diameters of all the three micelles, VES-g-PEI, OVA@VES-g-PEI, and OVA@mPEG-g-HA/VES-g-PEI displayed marginal changes within 14 days, indicative of good colloidal stability in PBS at pH 7.4. Meanwhile, the OVA@mPEG-g-HA/ VES-g-PEI micelle showed good serum stability in 10% FBS due to negatively charged of nanoparticle surface. More importantly, the CMC value of the VES-g-PEI micelle was 20.7 μg mL −1 (Fig. S2B) , far below the concentration when administered into the blood, suggesting its good thermodynamic stability. The in vitro OVA release profile of the OVA@mPEG-g-HA/VES-g-PEI micelle (Fig. 3B) showed that 15.2% of OVA was burst released from the micelle within initial 2 h, which was possibly related to the competitive binding of HA with PEI and the consequent weakening of OVA association. In the next 70 h, a sustained release of OVA up to 41.5% was observed.
Stability of the OVA@mPEG-g-HA/VES-g-PEI micelle and in vitro release of OVA
Table 2
Physicochemical properties of the OVA@mPEG-g-HA/VES-g-PEI micelle (weight ratio of OVA/VES-g-PEI fixed at 0.5/1) prepared at different feeding weight ratios of mPEG-g-HA relative to VES-g-PEI. (Mean ± SD, n = 5). 123.5 ± 6.5 −15.6 ± 0.9 14.2 ± 3.7 0.14 2/1 132.1 ± 0.2 −35.1 ± 1.5 13.6 ± 3.0 0.23 3/1 132.1 ± 1.3 −42.0 ± 1.2 9.7 ± 2.3 0.20
Note: EE: entrapment efficiency. LE: loading efficiency. PI: polydispersity index. 
In vitro cytotoxicity
The in vitro cytotoxicity of PEI, VES-g-PEI micelle, OVA@VES-g-PEI micelle, and OVA@mPEG-g-HA/VES-g-PEI micelle toward B16-F10 cells was examined (Fig. 3C) . As expected, the cationic polymer, PEI, exhibited considerable cytotoxicity (Yim et al., 2013) . With increasing the PEI concentration to 50-100 μg mL −1 , the cell viability was remarkably reduced to 10.4%. As comparison, viabilities of the cells treated with PEI, VES-g-PEI micelle, and OVA@VES-g-PEI micelle at the concentration of 100 μg mL −1 were 10.4%, 58.1% and 79.5%, respectively. The OVA@mPEG-g-HA/VES-g-PEI micelle showed the best cell viability within the entire concentration range tested. Grafting PEI with VES effectively decreased the PEI cytotoxicity, which could be attributed to the substitution of the amine groups of PEI by VES and the consequent reduction in the positive charge density. OVA@VES-g-PEI and OVA@mPEG-g-HA/VES-g-PEI micelle, in particular the latter, showed further improved cell viability, suggesting the favorable roles of negatively charged components OVA and HA through reduction of surface charge and PEG through its stealth effect.
Cellular uptake of OVA
The ability of the novel micellar platform to enhance cellular uptake of OVA in vitro was examined (Fig. 4B ) and was measured quantitatively by flow cytometry (Fig. 4D) . There was almost no green fluorescence in the B16-F10 cells treated with FITC-OVA alone, similar to the negative control group. This is because intracellular delivery of macromolecules, including proteins, peptides and nucleic acids, is commonly limited by cellular uptake and enzyme degradation in lysosomes (Savla et al., 2014) . As comparison, efficient internalization of the FITC-OVA@VES-g-PEI micelle in B16-F10 cells was observed, which was attributed to the net positive charge of the micelle surface (Zhao et al., 2011) as shown in Table 1 . The cells treated with the FITC-OVA@ mPEG-g-HA/VES-g-PEI micelle exhibited higher green fluorescence signals compared to the FITC-OVA@VES-g-PEI micelle. Despite the fact that the FITC-OVA@mPEG-g-HA/VES-g-PEI micelle displayed the net negative surface charge (Table 2) , which was regarded to be unfavorable for cell internalization since the plasma membrane is also negatively charged (Zhao et al., 2011) , and the PEG layer on the surface of nanoparticles has been reported to reduce the cellular uptake (Romberg et al., 2008) , the cellular uptake of the FITC-OVA@mPEG-g-HA/VES-g-PEI micelle increased by 11.9 fold. The enhanced cellular uptake should be attributed to the surface presence of HA, which can selectively target B16-F10 cells through CD44 receptor-mediated endocytosis . To further verify the mechanism, competitive binding test was performed by treating free HA molecules with cells before cellular uptake, the lower green fluorescence (Fig. 4B ) and mean fluorescence intensity (MFI) (Fig. 4B) proves HA can target CD44 receptors and enhance cellular uptake through receptor-mediated internalization.
Endosomal escape of OVA
To avoid antigen processing through the MHC II pathway in the endosome, PEI was used to assist antigen escaping from the endosome into the cytoplasm toward the MHC I pathway. Distribution of FITC-OVA in B16-F10 cells was examined via confocal microscopy to assess the ability of the novel micellar platform to facilitate endosomal escape (Fig. 4A) . For the cells treated with free FITC-OVA, the yellow color in the merged image proved that almost all the green fluorescently labeled OVA was co-localized with endosomes/lysosomes labeled with Lysotracker Red following endocytosis. Thanks to the proton buffer capability of the VES-g-PEI micelle, FITC-OVA escaped from the endosome into the cytoplasm, showing a bit stronger green fluorescence and significantly reduced yellow fluorescence compared with the free FITC-OVA. Considerably stronger green fluorescence was observed in the B16-F10 cells treated with the FITC-OVA@mPEG-g-HA/VES-g-PEI micelle, with negligible yellow fluorescence. This suggests that the cationic polymer PEI could facilitate endosomal escape towards the MHC I pathway, leading to effective presentation of the MHC I-OVA257-264 peptide on the melanoma cell surface followed by the recruitment of CTLs to kill cells.
BMDC maturation and in vitro antigen presentation
Dendritic cells (DCs) cell plays an essential role in adaptive immune responses as they capture and process antigen in draining lymph node and then the matured DCs can present to T cells to induce immune response (Randolph et al., 2005) . To evaluate the effect of OVA@ mPEG-g-HA/VES-g-PEI micelle on DCs in vitro, immature BMDCs were harvest on day 7 and exposed in OVA@mPEG-g-HA/VES-g-PEI micelle for another 2 days. DC maturation was determined by surface marker expression using flow cytometry. It can be found that OVA@mPEG-g-HA/VES-g-PEI micelle can significantly enhanced expression level of CD40 and CD80 which indicate the maturation of DCs (Fig. 5) . Moreover, compared with OVA group, the MFI of micelle group were 2.6 time higher and were same level with LPS group. All of these results demonstrate a facilitative role of micelle on DC maturation.
As for cancer immunotherapy via the CD8 + cytotoxic T lymphocytes (CTLs) pathway, a foreign antigen should bind to the MHC I molecule and form complex on the cell surface (Lee et al., 2015) . Presentation of the MHC complex (MHC I-OVA 257-264 ) on the surface of B16-F10 cells was quantitatively measured through flow cytometry (Fig. 6 ). The proportion of melanoma cells with surface presentation of the MHC I-OVA 257-264 peptide complex induced by the OVA@mPEG-g-HA/VES-g-PEI micelle was 10 times higher than that by free OVA. This is attributed to the ability of the mPEG-g-HA/VES-g-PEI micelle to efficiently facilitate endosomal escape of OVA into the cytoplasm, which as a result leads to significantly enhanced OVA binding to the MHC I molecule and consequent presentation of the MHC I-OVA 257-264 peptide complex on the melanoma cell surface.
In vivo biodistribution of micelles
Near-infrared fluorescence images in vivo was examined (Fig. S3) , then different organs of C57BL/6 mice administered with the micellar systems were taken to further evaluate in vivo distribution (Fig. 7) . For C57BL/6 mice administered by intravenous injection with the VES-g-PEI micelle, the strongest fluorescent signals were observed in liver. This could be because the nanoparticles with net positive surface charge could be easily eliminated by macrophage in liver, leading to shorter circulation time and reduced accumulation in tumor (Zhao et al., 2011) . As comparison, administration of mice with the mPEG-g-HA/VES-g-PEI micelle resulted in the strongest fluorescent signals in tumor followed by liver. The net negative surface charge of the multifunctional micellar system could considerably decrease phagocytosis of MPS and prolong circulation time. In addition, the targeting ligand HA present on the 
In vivo anti-tumor efficacy
To investigate the in vivo anti-tumor efficacy of the novel immunotherapeutic micellar platform through surface presentation of foreign antigen to CTLs, herein, C57BL/6 tumor-bearing mice were immunized with the OVA@mPEG-g-HA/VES-g-PEI micelle subcutaneously (Fig. 8A) . The up-regulated surface marker CD40 and CD80 indicated the maturation of DCs (Fig. 5) . As shown in Fig. 8B , the OVA group and the VES-g-PEI micelle group displayed similar tumor volumes as compared with the PBS group. In contract, for the OVA@mPEG-g-HA/VES-g-PEI micelle group, from the 18th day tumor volume was significantly smaller than the other groups, which suggests the improved tumor inhibition efficacy of the OVA@mPEG-g-HA/VES-g-PEI micelle. However, tumor volume still grew to 1000 mm 3 on the 20th day indicating a weak immune effect against tumor in a long-term therapy. In future work, we intend to target antigen presenting cells such as dendritic cells to elicit stronger foreign antigen-specific CTLs to target cancer cells which present foreign antigen to achieve an effective immunotherapy. Fig. 8C shows that body weight of the tumor-bearing mice in each group gradually increased due to tumor growth, which indicates that the OVA@mPEG-g-HA/VES-g-PEI micelle might not induce severe toxicity in vivo.
Conclusion
It is known that neoantigen can induce immunological rejection of tumors. In this work, a novel immunotherapeutic micellar carrier has been successfully developed to effectively delivery foreign antigen to tumor cells and present the MHC I-OVA 257-264 peptide complex on the B16-F10 cell surface. This immunotherapeutic micelle exhibits several main advantages: 1) The micelle has favorable physicochemical property with good stability and low cytotoxicity; 2) The micelle surface was coated with HA, which can delivery antigen to tumor cells; 3) PEI can assist antigen escaping from the endosome into the cytoplasm toward the MHC I pathway, leading to neoantigen recognition by cytotoxic T lymphocytes (CTLs). All these results suggest the potential immunotherapeutic application of the OVA@mPEG-g-HA/VES-g-PEI micelle for treatment of cancers including melanoma.
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